Stebbing J - Search Results

1

Novel immunotherapeutic drugs for the treatment of lung cancer.

Peng L, Wang Z, Stebbing J, Yu Z. Peng L, et al. Among authors: stebbing j. Curr Opin Oncol. 2022 Jan 1;34(1):89-94. doi: 10.1097/CCO.0000000000000800. Curr Opin Oncol. 2022. PMID: 34636350 Review.

2

Managing patients with cancer in the COVID-19 era.

Peng L, Zagorac S, Stebbing J. Peng L, et al. Among authors: stebbing j. Eur J Cancer. 2020 Jun;132:5-7. doi: 10.1016/j.ejca.2020.03.028. Epub 2020 Apr 11. Eur J Cancer. 2020. PMID: 32302754 Free PMC article. No abstract available.

3

Lessons to Europe from China for cancer treatment during the COVID-19 pandemic.

Peng L, Yang JS, Stebbing J. Peng L, et al. Among authors: stebbing j. Br J Cancer. 2020 Jul;123(1):7-8. doi: 10.1038/s41416-020-0856-0. Epub 2020 May 14. Br J Cancer. 2020. PMID: 32409750 Free PMC article.

4

A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.

Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. Peng L, et al. Among authors: stebbing j. Expert Opin Drug Saf. 2020 Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31. Expert Opin Drug Saf. 2020. PMID: 32693646

5

Reply to letter to the editor: baricitinib and toxicity is a rare occurrence.

Peng L, Stebbing J, Wang YJ. Peng L, et al. Among authors: stebbing j. Expert Opin Drug Saf. 2020 Oct;19(10):1371-1372. doi: 10.1080/14740338.2020.1812192. Epub 2020 Aug 24. Expert Opin Drug Saf. 2020. PMID: 32804556 No abstract available.

6

A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy.

Peng L, Qin BD, Xiao K, Xu S, Yang JS, Zang YS, Stebbing J, Xie LP. Peng L, et al. Among authors: stebbing j. Oncoimmunology. 2020 Jun 26;9(1):1781333. doi: 10.1080/2162402X.2020.1781333. Oncoimmunology. 2020. PMID: 32923143 Free PMC article.

7

Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review.

Peng L, Mao QQ, Jiang B, Zhang J, Zhao YL, Teng XD, Yang JS, Xia Y, Chen SQ, Stebbing J, Jiang H. Peng L, et al. Among authors: stebbing j. Front Oncol. 2020 Nov 9;10:549168. doi: 10.3389/fonc.2020.549168. eCollection 2020. Front Oncol. 2020. PMID: 33240807 Free PMC article.

8

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC.

Peng L, Xiao K, Cui J, Ye XH, Zhang YC, Mao L, Selvaggi G, Yen J, Stebbing J. Peng L, et al. Among authors: stebbing j. Onco Targets Ther. 2021 May 25;14:3409-3415. doi: 10.2147/OTT.S310756. eCollection 2021. Onco Targets Ther. 2021. PMID: 34079286 Free PMC article.

9

EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes.

Jin R, Peng L, Shou J, Wang J, Jin Y, Liang F, Zhao J, Wu M, Li Q, Zhang B, Wu X, Lan F, Xia L, Yan J, Shao Y, Stebbing J, Shen H, Li W, Xia Y. Jin R, et al. Among authors: stebbing j. Front Oncol. 2021 Jun 14;11:680804. doi: 10.3389/fonc.2021.680804. eCollection 2021. Front Oncol. 2021. PMID: 34195081 Free PMC article.

10

First-Line Treatment Options for PD-L1-Negative Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis.

Peng L, Liang WH, Mu DG, Xu S, Hong SD, Stebbing J, Liang F, Xia Y. Peng L, et al. Among authors: stebbing j. Front Oncol. 2021 Jun 23;11:657545. doi: 10.3389/fonc.2021.657545. eCollection 2021. Front Oncol. 2021. PMID: 34249693 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

663 results

Search Page